In this issue:
Deep gray matter volume loss drives disability worsening in MS
Thalamic atrophy in MS
Central vein sign differentiates MS from CNS inflammatory vasculopathies
Activation of disease during therapy with alemtuzumab in 3 MS patients
Antibody response to influenza vaccination in MS patients receiving immunomodulatory therapy
Efficacy outcomes in vitamin D supplement users in the FREEDOMS trials
Smoking at time of CIS increases the risk of CDMS
Effectiveness and baseline factors associated to fingolimod response
Cerebellum, cognition and fall status in MS
Half-dose fingolimod for treating RRMS
Please login below to download this issue (PDF)